Vall d'Hebron Research Institute, Vall d'Hebron University Hospital, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.
Diabetes Care. 2023 Sep 1;46(9):1633-1639. doi: 10.2337/dc22-2521.
Early worsening of diabetic retinopathy (EWDR) due to the rapid decrease of blood glucose levels is a concern in diabetes treatment. The aim of the current study is to evaluate whether this is an important issue in subjects with type 2 diabetes with mild or moderate nonproliferative DR (NPDR), who represent the vast majority of subjects with DR attended in primary care.
This is a retrospective nested case-control study of subjects with type 2 diabetes and previous mild or moderate NPDR. Using the SIDIAP ("Sistema d'informació pel Desenvolupament de la Recerca a Atenció Primària") database, we selected 1,150 individuals with EWDR and 1,150 matched control subjects (DR without EWDR). The main variable analyzed was the magnitude of the reduction of HbA1c in the previous 12 months. The reduction of HbA1c was categorized as rapid (>1.5% reduction in <12 months) or very rapid (>2% in <6 months).
We did not find any significant difference in HbA1c reduction between case and control subjects (0.13 ± 1.21 vs. 0.21 ± 1.18; P = 0.12). HbA1c reduction did not show significant association with worsening of DR, neither in the unadjusted analyses nor in adjusted statistical models that included the main confounding variables: duration of diabetes, baseline HbA1c, presence of hypertension, and antidiabetic drugs. In addition, when stratification by baseline HbA1c was performed, we did not find that those patients with higher levels of HbA1c presented a higher risk to EWDR.
Our results suggest that the rapid reduction of HbA1c is not associated with progression of mild or moderate NPDR.
由于血糖水平的快速下降导致糖尿病视网膜病变(DR)的早期恶化(EWDR)是糖尿病治疗中的一个关注点。本研究旨在评估对于在基层医疗就诊的 DR 患者中占绝大多数的 2 型糖尿病合并轻度或中度非增生性 DR(NPDR)患者,这种情况是否是一个重要问题。
这是一项回顾性巢式病例对照研究,研究对象为患有 2 型糖尿病且既往患有轻度或中度 NPDR 的患者。我们使用 SIDIAP(“初级保健研究和发展信息系统”)数据库,选择了 1150 例 EWDR 患者和 1150 例匹配对照患者(DR 无 EWDR)。分析的主要变量是过去 12 个月中 HbA1c 的降低幅度。HbA1c 的降低幅度分为快速(<12 个月内降低>1.5%)或非常快速(<6 个月内降低>2%)。
我们未发现病例组和对照组之间的 HbA1c 降低幅度有显著差异(0.13 ± 1.21 对 0.21 ± 1.18;P = 0.12)。在未调整分析和包括主要混杂变量(糖尿病病程、基线 HbA1c、高血压和抗糖尿病药物)的调整后统计模型中,HbA1c 降低与 DR 恶化均无显著相关性。此外,当按基线 HbA1c 进行分层时,我们发现 HbA1c 水平较高的患者并没有更高的 EWDR 风险。
我们的研究结果表明,HbA1c 的快速降低与轻度或中度 NPDR 的进展无关。